A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable 2 (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian EPZ015666 site italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Lowered risk Later age of onset No risk association No risk association No risk association Decreased Enasidenib danger of eR+ BC No threat association enhanced general threat No threat association increased risk of eR- BC increased threat elevated threat No danger association elevated threat No risk association elevated threat No risk association elevated risk No threat association increased danger No danger association Decreased risk No danger association improved overall danger No risk association No danger association enhanced general threat No risk association Decreased risk of eR+ BC elevated risk of eR- BC No danger association Decreased risk No danger association elevated danger of eR+ No danger association No threat association Decreased risk of eR- BC Decreased danger of eR+ BC No danger association Decreased danger of eR+ No risk association No threat association improved general risk Decreased overall threat No threat association No danger association increased risk of eR- BC increased risk increased threat increased risk improved risk in eR+ earlier age of onset increased risk (A allele) earlier age of onset (C allele) Decreased risk Decreased risk increased danger Reduced survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 three UTR BMPR1B three UTR BRCA1 3 UTR HPGD 3 UTR IGF-1R 3 UTR IL23R 3 UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 3 UTR ITGB4 3 UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable two (Continued)miRNA locus KRAS 3 UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation increased frequency in BRCA1 carriers/no threat association enhanced danger of TNBC Decreased danger enhanced danger and poor survival earlier age of onset enhanced danger enhanced risk Decreased danger Decreased overall risk No risk association Decreased danger of eR+ BC No danger association increas.A/G rs12983273 T/C(Continued)Breast Cancer: Targets and Therapy 2015:submit your manuscript | www.dovepress.comDovepressGraveel et alDovepressTable 2 (Continued)Gene locus MIR423 SNP rs6505162 A/C Comments premiRNA Population Caucasian Jewish BRCA2 carriers Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans Chinese Asians Caucasians Asians Caucasians Chinese Caucasians Asians Caucasians Asians Caucasians Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Asians Caucasians African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans African Americans european Americans Jewish BRCA2 carriers Caucasian italian Chinese Jewish BRCA1 carriers Chinese Clinical observation Decreased danger Later age of onset No danger association No danger association No threat association Decreased danger of eR+ BC No threat association improved general danger No threat association improved danger of eR- BC improved threat improved danger No risk association increased danger No threat association increased danger No risk association elevated risk No risk association enhanced danger No danger association Decreased danger No threat association improved overall danger No risk association No risk association increased overall risk No danger association Decreased risk of eR+ BC increased risk of eR- BC No danger association Decreased risk No threat association increased danger of eR+ No threat association No risk association Decreased risk of eR- BC Decreased threat of eR+ BC No danger association Decreased threat of eR+ No threat association No threat association enhanced general danger Decreased general risk No danger association No danger association improved threat of eR- BC enhanced danger increased danger elevated threat improved threat in eR+ earlier age of onset increased danger (A allele) earlier age of onset (C allele) Decreased threat Decreased threat increased danger Lowered survival Reference 150 142 38 33 33 33 36 151 152 32 147 153 31 141 33 33 33 33 141 33 33 33 33 33 33 33 142 srep39151 43 154 155 156 jir.2014.0227 157 158 159MIR455 MIR487 MIR495 MIRrs2060133 C/G rs1951032 G/A rs2281611 C/A rs3746444 A/Grs3746444 T/CMIR513A-2 MIR544 MIR548A-2 MIR595 MIR605 MIR606 MIR608 MIRrs2018562 A/G rs10144193 A/T rs878175 A/G rs4909238 A/G rs2043556 *A rs12266981 G/A rs4919510 C/G rs8041885 A/G rs8041044 C/AMIR659 MIRrs5750504 T/A rs12586258 G/A rs7141987 A/GATF1 three UTR BMPR1B 3 UTR BRCA1 three UTR HPGD 3 UTR IGF-1R 3 UTR IL23R three UTRrs11169571 C/T rs1434536 C/T rs799917 C/T rs8752 G/A rs28674628 A/G rs10889677 A/CmiR320 MRe miR125b MRe miR638 MRe miR4855p MRe miR5155p MRe let7 MReIQGAP1 3 UTR ITGB4 three UTRrs1042538 A/T rs743554 A/GmiR124 MRe miR34a MRepredictedChinese Swedish(Continued)submit your manuscript | www.dovepress.comBreast Cancer: Targets and Therapy 2015:DovepressDovepressmicroRNAs in breast cancerTable two (Continued)miRNA locus KRAS three UTR SNP rs61764370 T/G Comments let7 MRe Population Caucasian Clinical observation increased frequency in BRCA1 carriers/no danger association enhanced threat of TNBC Decreased risk enhanced danger and poor survival earlier age of onset enhanced risk increased risk Decreased risk Decreased general threat No danger association Decreased risk of eR+ BC No risk association increas.
